The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in depressive disorders, providing a more comprehensive basis for the application of TI technology.
Participants must be aged between 18 and 65, with no gender restrictions;
A diagnosis of depression made by the study physician based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
HAMD-17 score of 17 or higher;
Participants must not have changed their antidepressant medication regimen from 30 days prior to signing the informed consent form through the duration of the experiment;
Eligible participants must not have a history of psychiatric or neurological disorders, as judged by the investigator, which may impact the evaluation of the study's efficacy;
Participants must not have a history of seizures or prior episodes of epilepsy;
The presence of metallic foreign objects within the cranial structure or metallic cardiac implants;
Participants must not have a diagnosis of organic brain disease, nor a history of significant cranial trauma or neurosurgical intervention;
Single group
Nervio-X
DeviceAn 8-channel TIS device developed by NEURODOME Corporation.
HAMD-17
HAMA
HAMA is a questionnaire that designed to evaluate the presence and intensity of anxiety symptoms in both clinical and research settings.
SHAPS
The SHAPS is a questionnaire that used to measure the severity of anhedonia, a common symptom in various mental health conditions.
SF-36
WHOQOL-BREF
Click on the lead sponsor to view all of their trials.
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Lead sponsor
Ruijin Hospital
Collaborator
